CRA provided expert testimony in litigation involving allegations that fraudulent reporting of list prices by pharmaceutical manufacturers affected reimbursement by insurers. CRA’s analyses addressed important features underlying pricing and reimbursement in the pharmaceutical industry, including the role of list prices and price reporting publications, the evolution of pricing mechanisms as a basis for reimbursement, and information held by various parties concerning pharmaceutical acquisition costs.
Alzheimer Europe 2025: Prioritising Alzheimer’s Disease policy in Europe
Building upon the findings of a recent CRA report, which synthesised insights from a roundtable of AD experts, Prioritising Alzheimer’s disease policy in...